4//SEC Filing
Chakma Justin 4
Accession 0001951238-25-000005
CIK 0001671858other
Filed
Nov 13, 7:00 PM ET
Accepted
Nov 14, 6:42 PM ET
Size
10.6 KB
Accession
0001951238-25-000005
Insider Transaction Report
Form 4
Chakma Justin
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2025-11-12$0.84/sh+30,000$25,200→ 166,380 total - Sale
Common Stock
2025-11-12$8.91/sh−30,000$267,357→ 136,380 total - Sale
Common Stock
2025-11-12$8.86/sh−136,380$1,208,790→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-12−30,000→ 89,047 totalExercise: $0.84Exp: 2029-07-04→ Common Stock (30,000 underlying)
Footnotes (3)
- [F1]The weighted average sale price for the transaction reported was $8.9119, and the range of prices was between $8.87 and $8.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F2]The weighted average sale price for the transaction reported was $8.8634, and the range of prices was between $8.62 and $9.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F3]Immediately exercisable.
Documents
Issuer
ARS Pharmaceuticals, Inc.
CIK 0001671858
Entity typeother
Related Parties
1- filerCIK 0001951238
Filing Metadata
- Form type
- 4
- Filed
- Nov 13, 7:00 PM ET
- Accepted
- Nov 14, 6:42 PM ET
- Size
- 10.6 KB